InfYnity Biomarkers is glad to announce that it will participate in a two-year, $594,008 Small Business Innovative Research (SBIR) grant, awarded to Kephera Diagnostics (Framingham, MA) and partners, by The National Institute of Allergy and Infectious Diseases, an agency of the National Institutes of Health (NIH).
Chagas disease affects the life of up to 65 million people which are at high risk of infection by T. cruzi living in high transmission areas. In spite of important ongoing multinational initiatives, patients still lack adequate drug treatments. Today clinicians cannot evaluate if a drug treatment has been successful or not. This is an important concern not only for the development of novel drugs but also for evaluation of clinical trials and the clinical management of patients.
To address this medical need, Kephera Diagnostics and InfYnity Biomarkers, as well as their partners Vitalant Research Institute (San Francisco, CA) and the Institute of Tropical Medicine at the University of Sao Paulo (Sao Paulo, Brazil), now aim to develop a rapid test to assess treatment efficacy in a timely manner.
This collaboration acknowledges the high-level of expertise developed by InfYnity in the field of infectious diseases and corresponding immune signatures.